Cite
Figure S4 from Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial
MLA
Olivier Louis Chinot, et al. Figure S4 from Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial. Mar. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....9a3ccfb78496291f6e62e1bdd120eb2a&authtype=sso&custid=ns315887.
APA
Olivier Louis Chinot, Henry Dufour, Anne Barlier, Dominique Figarella-Branger, Karine Baumstarck, Mohamed Boucekine, Stéphane Honoré, Anita Cohen, Maryline Barrie, Emeline Tabouret, Stéphane Fuentes, Pierre-Hugues Roche, Michel Kalamarides, Catherine Roche, Didier Autran, Noémie Basset, Hadrien Peyrière, Matthieu Peyre, Ahmed Idbaih, … Thomas Graillon. (2023). Figure S4 from Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
Chicago
Olivier Louis Chinot, Henry Dufour, Anne Barlier, Dominique Figarella-Branger, Karine Baumstarck, Mohamed Boucekine, Stéphane Honoré, et al. 2023. “Figure S4 from Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial,” March. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....9a3ccfb78496291f6e62e1bdd120eb2a&authtype=sso&custid=ns315887.